Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The study will investigate if CDK4/6 inhibitor holiday will reset the cell cycle process to respond to the combination of fulvestrant and abemaciclib, and this approach may represent an effective therapeutic strategy to manage such patients.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek powyżej 18 lat.
- •Nowotwór piersi z przerzutami, potwierdzony badaniem histologicznym, dodatni na receptor estrogenowy, ujemny na receptor HER2.
- •Progresja choroby mimo leczenia inhibitorem CDK4/6 z inhibitorem aromatazy bezpośrednio przed wpisaniem do badania.
- •Zmierzone zmiany nowotworowe widoczne w badaniach obrazowych lub choroba kostna.
- •Status pomenopauzalny lub leczenie leczeniem supresyjnym jajników.
- •Dobry stan ogólny pacjenta (zdolność do codziennych aktywności).
- •Przewidywana długość życia co najmniej 6 miesięcy.
- •Wystarczająca funkcja narządów (prawidłowe wyniki morfologii i enzymów wątrobowych).
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- January 28, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Houston Methodist Cancer Center
Houston, United States
Trial contact
Polly Niravath, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.